Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
This study has been completed.
Study NCT00028899 Information provided by National Cancer Institute (NCI)
First Received: January 4, 2002 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Preleukemia
Syndrome
More general conditions related to this trial
Bone Marrow Diseases
Disease
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
asparaginase
cytarabine
gemtuzumab ozogamicin
mitoxantrone hydrochloride
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Gemtuzumab
Mitoxantrone
More general drug interventions related to this trial
Analgesics
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Children's Oncology Group
National Cancer Institute (NCI)
Back to top of Main Content
